BlackRock Discloses 5.0% Stake in ZEVRA THERAPEUTICS
Ticker: ZVRA · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | SC 13G |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, pharmaceuticals
TL;DR
**BlackRock just revealed a 5% stake in ZEVRA, a bullish signal for the pharma stock.**
AI Summary
BlackRock Inc., a massive investment management firm, reported on January 29, 2024, that it beneficially owns 2,058,943 shares of ZEVRA THERAPEUTICS, INC. (formerly KEMPHARM, INC.) Common Stock as of December 31, 2023. This represents a 5.0% ownership stake in the pharmaceutical company. This matters to investors because BlackRock's significant holding indicates their confidence in ZEVRA, and any future changes in their position could influence the stock's perception and price.
Why It Matters
BlackRock's substantial 5.0% ownership in ZEVRA THERAPEUTICS signals a notable institutional endorsement, which can positively influence investor sentiment and potentially attract further investment.
Risk Assessment
Risk Level: low — This filing indicates a large institutional investor has a significant stake, which generally adds stability rather than risk.
Analyst Insight
A smart investor would view BlackRock's 5.0% stake as a vote of confidence, potentially warranting further research into ZEVRA THERAPEUTICS, INC.'s fundamentals and future prospects, especially given its pharmaceutical industry classification.
Key Numbers
- 2,058,943 — Shares Beneficially Owned (The total number of ZEVRA THERAPEUTICS, INC. shares BlackRock Inc. holds.)
- 5.0% — Ownership Percentage (The percentage of ZEVRA THERAPEUTICS, INC. common stock owned by BlackRock Inc.)
Key Players & Entities
- BlackRock Inc. (company) — the investment management firm filing the SC 13G
- ZEVRA THERAPEUTICS, INC. (company) — the subject company in which BlackRock holds shares
- KEMPHARM, INC. (company) — former name of ZEVRA THERAPEUTICS, INC.
- 2,058,943 (dollar_amount) — number of shares beneficially owned by BlackRock Inc.
- 5.0% (dollar_amount) — percentage of ZEVRA THERAPEUTICS, INC. stock owned by BlackRock Inc.
- December 31, 2023 (date) — date of the event requiring the filing
- January 29, 2024 (date) — date the SC 13G filing was made
Forward-Looking Statements
- ZEVRA THERAPEUTICS, INC. stock may see increased investor interest due to BlackRock's significant stake. (ZEVRA THERAPEUTICS, INC.) — medium confidence, target: Next 3-6 months
FAQ
Who filed this SC 13G statement?
This SC 13G statement was filed by BlackRock Inc., a major investment management firm based in New York, NY.
What company's stock is the subject of this filing?
The subject company of this filing is ZEVRA THERAPEUTICS, INC., which was formerly known as KEMPHARM, INC.
What percentage of ZEVRA THERAPEUTICS, INC. stock does BlackRock Inc. beneficially own?
BlackRock Inc. beneficially owns 5.0% of the Common Stock of ZEVRA THERAPEUTICS, INC.
How many shares of ZEVRA THERAPEUTICS, INC. does BlackRock Inc. beneficially own?
BlackRock Inc. beneficially owns 2,058,943 shares of ZEVRA THERAPEUTICS, INC. Common Stock.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 regarding ZEVRA THERAPEUTICS, INC. (ZVRA).